Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn’s Disease

Nathalie Van den Berghe(KU Leuven), Paul Declerck(KU Leuven), Debby Thomas(KU Leuven), Séverine Vermeire(KU Leuven), Bram Verstockt(Universitair Ziekenhuis Leuven)

Clinical Gastroenterology and Hepatology

December 20, 2021

10.1016/j.cgh.2021.12.020

Cited by 7

Related Papers

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease

|Nature Genetics|2008|2.6k

A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis

|Gut|2013|1.9k

ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications

|Journal of Crohn s and Colitis|2018|1.8k

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

|New England Journal of Medicine|2016|1.8k

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment

|Journal of Crohn s and Colitis|2019|1.4k